Total Payments
$156,063
2024 Payments
$47,871
Companies
17
Transactions
94
Medicare Patients
975
Medicare Billing
$304,430
Payment Breakdown by Category
Consulting$86,216 (55.2%)
Other$57,320 (36.7%)
Travel$7,562 (4.8%)
Food & Beverage$2,612 (1.7%)
Research$2,354 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $86,216 | 32 | 55.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $54,952 | 18 | 35.2% |
| Travel and Lodging | $7,562 | 8 | 4.8% |
| Food and Beverage | $2,612 | 31 | 1.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,368 | 1 | 1.5% |
| Unspecified | $2,354 | 4 | 1.5% |
Payments by Type
General
$153,710
90 transactions
Research
$2,354
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $62,045 | 39 | $0 (2024) |
| Amgen Inc. | $49,184 | 18 | $0 (2024) |
| GENZYME CORPORATION | $12,723 | 3 | $0 (2024) |
| PFIZER INC. | $7,014 | 6 | $0 (2023) |
| GlaxoSmithKline, LLC. | $6,500 | 1 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $5,240 | 2 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,805 | 3 | $0 (2023) |
| JAZZ PHARMACEUTICALS INC. | $3,200 | 1 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $3,143 | 6 | $0 (2022) |
| Astellas Pharma Global Development | $2,337 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $47,871 | 28 | Adaptive Biotechnologies Corporation ($26,078) |
| 2023 | $47,971 | 28 | Adaptive Biotechnologies Corporation ($35,527) |
| 2022 | $24,222 | 15 | Amgen Inc. ($11,490) |
| 2021 | $12,432 | 7 | Novartis Pharmaceuticals Corporation ($5,240) |
| 2020 | $4,588 | 2 | Amgen Inc. ($4,588) |
| 2019 | $11,178 | 2 | Amgen Inc. ($8,438) |
| 2018 | $7,603 | 8 | Amgen Inc. ($5,368) |
| 2017 | $199.37 | 4 | Incyte Corporation ($160.58) |
All Payment Transactions
94 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Amgen Inc. | Blincyto (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,000.00 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $109.71 | General |
| Category: ONCOLOGY | ||||||
| 09/26/2024 | Amgen Inc. | Blincyto (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,430.00 | General |
| Category: Oncology | ||||||
| 09/14/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $146.79 | General |
| Category: Oncology | ||||||
| 08/01/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Consulting Fee | Cash or cash equivalent | $4,800.00 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Travel and Lodging | Cash or cash equivalent | $496.98 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Travel and Lodging | Cash or cash equivalent | $376.95 | General |
| Category: ONCOLOGY | ||||||
| 08/01/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Travel and Lodging | Cash or cash equivalent | $273.28 | General |
| Category: ONCOLOGY | ||||||
| 07/12/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $14.58 | General |
| Category: ONCOLOGY | ||||||
| 07/10/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $100.60 | General |
| Category: ONCOLOGY | ||||||
| 07/01/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $131.18 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2024 | Astellas Pharma Global Development | Xospata (Drug) | Food and Beverage | In-kind items and services | $116.28 | General |
| Category: Oncology | ||||||
| 05/02/2024 | Amgen Inc. | Blincyto (Biological) | Travel and Lodging | Cash or cash equivalent | $5,585.50 | General |
| Category: Oncology | ||||||
| 05/02/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Consulting Fee | Cash or cash equivalent | $5,200.00 | General |
| Category: ONCOLOGY | ||||||
| 05/02/2024 | Amgen Inc. | Blincyto (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,439.50 | General |
| Category: Oncology | ||||||
| 05/02/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Travel and Lodging | Cash or cash equivalent | $139.36 | General |
| Category: ONCOLOGY | ||||||
| 04/25/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: ONCOLOGY | ||||||
| 04/25/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $26.61 | General |
| Category: ONCOLOGY | ||||||
| 04/18/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Travel and Lodging | Cash or cash equivalent | $341.70 | General |
| Category: ONCOLOGY | ||||||
| 04/18/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Travel and Lodging | Cash or cash equivalent | $293.26 | General |
| Category: ONCOLOGY | ||||||
| 04/04/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Consulting Fee | Cash or cash equivalent | $6,800.00 | General |
| Category: ONCOLOGY | ||||||
| 02/29/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Consulting Fee | Cash or cash equivalent | $4,400.00 | General |
| Category: ONCOLOGY | ||||||
| 02/29/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: ONCOLOGY | ||||||
| 02/20/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $29.25 | General |
| Category: Hematology | ||||||
| 01/30/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $16.17 | General |
| Category: Hematology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An assessment of treatment outcomes in a historical cohort of patients with relapsed or refractory | Amgen Inc. | $1,609 | 2 |
| Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults | Amgen Inc. | $722.15 | 1 |
| Ph3 Adult ALLRandomised Confirmatory Study - TOWER study | Amgen Inc. | $22.38 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 277 | 854 | $348,179 | $89,109 |
| 2022 | 6 | 227 | 791 | $300,977 | $77,873 |
| 2021 | 6 | 255 | 716 | $260,412 | $70,824 |
| 2020 | 5 | 216 | 710 | $261,204 | $66,623 |
Total Patients
975
Total Services
3,071
Medicare Billing
$304,430
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 71 | 405 | $115,405 | $38,923 | 33.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 89 | 324 | $172,630 | $35,434 | 20.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 56 | 58 | $34,812 | $8,076 | 23.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 47 | 53 | $17,340 | $4,629 | 26.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 14 | 14 | $7,992 | $2,048 | 25.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 60 | 403 | $114,065 | $33,487 | 29.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 73 | 282 | $145,494 | $32,604 | 22.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 32 | 37 | $20,202 | $5,932 | 29.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 33 | 35 | $10,465 | $2,966 | 28.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 16 | 16 | $8,666 | $2,413 | 27.8% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2022 | 13 | 18 | $2,085 | $470.57 | 22.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 61 | 361 | $102,163 | $30,305 | 29.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 66 | 215 | $106,539 | $25,379 | 23.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 53 | 55 | $28,985 | $8,602 | 29.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 44 | 46 | $13,248 | $3,944 | 29.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 12 | 12 | $6,440 | $1,834 | 28.5% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2021 | 19 | 27 | $3,037 | $760.40 | 25.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 62 | 385 | $108,955 | $33,080 | 30.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 69 | 236 | $112,922 | $21,313 | 18.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 42 | 45 | $22,905 | $7,540 | 32.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 26 | 27 | $7,506 | $2,394 | 31.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 17 | 17 | $8,916 | $2,296 | 25.8% |
About Dr. Nicholas Short, MD
Dr. Nicholas Short, MD is a Hematology & Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/08/2011. The National Provider Identifier (NPI) number assigned to this provider is 1396039178.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nicholas Short, MD has received a total of $156,063 in payments from pharmaceutical and medical device companies, with $47,871 received in 2024. These payments were reported across 94 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($86,216).
As a Medicare-enrolled provider, Short has provided services to 975 Medicare beneficiaries, totaling 3,071 services with total Medicare billing of $304,430. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Internal Medicine
- Location Houston, TX
- Active Since 06/08/2011
- Last Updated 11/09/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1396039178
Products in Payments
- clonoSEQ (Device) $62,045
- Blincyto (Biological) $42,728
- ELITEK (Biological) $6,741
- BESPONSA (Biological) $3,834
- ICLUSIG (Drug) $3,805
- RYLAZE (Drug) $3,200
- LUMOXITI (Drug) $2,740
- Xospata (Drug) $2,484
- REBLOZYL (Biological) $66.22
- BOSULIF (Drug) $30.04
- EPKINLY (Drug) $26.61
- MONJUVI (Drug) $14.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Houston
Devesh Pandya, M.d, M.D
Hematology & Oncology — Payments: $1.8M
Hematology & Oncology $1.8M
Elias Jabbour, M.d, M.D
Hematology & Oncology — Payments: $1.6M
Hematology & Oncology $1.6M
Dr. Naval Daver, Mbbs, MBBS
Hematology & Oncology — Payments: $983,097
Hematology & Oncology $983,097
Jorge Cortes-Franco, M.d, M.D
Hematology & Oncology — Payments: $927,016
Hematology & Oncology $927,016
Dr. Luis Camacho, M.d., Mph, M.D., MPH
Hematology & Oncology — Payments: $491,819
Hematology & Oncology $491,819
Christopher Flowers, M.d, M.D
Hematology & Oncology — Payments: $320,001
Hematology & Oncology $320,001